



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ





شبكة المعلومات الجامعية



# شبكة المعلومات الجامعية

## التوثيق الالكتروني والميكرو فيلم

# جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأفلام قد اعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15 – 20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of  
15 – 25c and relative humidity 20-40 %



شبكة المعلومات الجامعية



# بعض الوثائق الأصلية تالفة



شبكة المعلومات الجامعية



بالرسالة صفحات  
لم ترد بالأصل

**BIOCHEMICAL STUDY ON THE INCIDENCE OF  
HEPATITIS C VIRUS INFECTION AMONG PATIENTS  
WITH CHRONIC LIVER DISEASE AND MEDICAL  
STAFF OF AN EGYPTIAN HOSPITAL**

**Thesis**

Submitted For The Ph.D Degree In Biochemistry

By

*Nadia Hamdan Mahmoud*

**Under Supervision**

*Prof. Dr. Mohamed M. Abdel Fattah*

Professor of Biochemistry

The Dean of Faculty of Science,

Ain Shams University

*M. A. Fattah*

*Prof. Dr. Ali Khalifa Ali*

Professor of Biochemistry

Head of Oncology Diagnostic Unit

Faculty of Medicine,

Ain Shams University.

*A. L.*

*Prof. Dr. Ibrahim H. Borai*

Professor of Biochemistry

Faculty of Science,

Ain Shams University

*I. H. Borai*

*Prof. Dr. Mostafa K. Mohamed*

Professor of hygiene environmental  
and Occupational medicine

Faculty of Medicine,

Ain Shams University

*M. K. Mohamed*

**Department of Biochemistry  
Faculty of Science, Ain Shams University  
1999**

*Boc IV*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ  
الْحَمْدُ لِلَّهِ الَّذِي  
خَلَقَ السَّمَوَاتِ وَالْأَرْضَ  
وَالَّذِي يُرِيهِمْ آيَاتِهِ وَيُخَوِّدُهُمْ  
فِيهَا وَلَهُ يُنِيبُ



## ACKNOWLEDGMENT

I wish to express my everlasting gratitude to **Prof. Dr. Mohamed Mohamed Abdel Fattah**, The Dean of Faculty of Science, Ain Shams University, for giving me the privilege of working under his supervision as well as his kind attitudes and moral supports. No words of appreciation are sufficient for his generous cooperation.

I am deeply grateful and appreciated to **Prof. Dr. Ali Khalifa Ali**, Professor of Biochemistry and Head of Oncology Diagnostic Unit, Faculty of Medicine, Ain Shams University. It was through his valuable advice, supervision, constant support and encouragement, his revision of all details and discussion of all results that made this work possible.

My cordial thanks to Prof. Dr. Ibrahim H. Borai, Professor of Biochemistry, Faculty of Science, Ain Shams University. For his kind supervision, care and useful advice growing out of his deep experience in this work.

I appreciate the generous help offered to me by **Prof. Dr. Mostafa K. Mohamed**. Professor of Community medicine, Faculty of Medicine, Ain Shams University, who spent a lot of his time and effort throughout this work and for his helpful guidance and unlimited support.

Finally I would like to express my thanks to **Dr. Mahmoud I. Hassan**, Professor of Biochemistry, Faculty of Medicine, Ain Shams University. It was through his constant support that made this work could be finally completed.

It is pleasure to acknowledge the help I have received from the members staff of the Gastroenterology Department of Egypt Air Hospital and Oncology Diagnostic Unit.



## ABBREVIATION

|                    |   |
|--------------------|---|
| AFP                | Alpha fetoprotein                               |
| ALP                | Alkaline phosphatase                            |
| ALT                | Alanine transaminase                            |
| AST                | Aspartate transaminase                          |
| CAH                | Chronic active hepatitis                        |
| CDNA               | Complementary DNA                               |
| CEA                | Carcinoembryonic antigen                        |
| CLD                | Chronic liver disease                           |
| DNA                | Deoxy ribo nucleic acid                         |
| E <sub>1</sub>     | Envelope region 1                               |
| E <sub>2</sub>     | Envelope region 2                               |
| ELISA              | Enzyme linked immunosorbant assay               |
| H.S.M              | Hepatosplenomegaly                              |
| HB <sub>c</sub> Ab | Hepatitis B core antibodies                     |
| HB <sub>s</sub> Ab | Hepatitis B surface antibodies                  |
| HB <sub>s</sub> Ag | Hepatitis B surface antigen                     |
| HBV                | Hepatitis B virus                               |
| HCC                | Hepatocellular carcinoma                        |
| HCV                | Hepatitis C virus                               |
| IFN                | Interferon                                      |
| NSI                | Non structural region 1                         |
| RIBA               | Recombinant - immunoblotting assay              |
| RNA                | Ribonucleic acid                                |
| RT-PCR             | Reverse Transcription polymerase chain reaction |
| T.BIL              | Total bilirubin                                 |
| TBE                | Tris - Borate EDTA                              |
| OR.                | Odds ratio                                      |

# List of Tables

|   | Page |
|---|------|
| Table (1)    Prevalence of HCV infection among healthy subjects<br>like blood donors.                           | 20   |
| Table (2)    Tentative pretreatment predictors of response to alpha<br>interferon therapy in chronic hepatitis. | 52   |
| Table (3)    Mean age of medical personnel group.   | 84   |
| Table (4)    Prevalence of HCV infection among medical personnel.   | 85   |
| Table (5)    The relation between HCV Infection and marriage.   | 87   |
| Table (6)    The relation between marriage and age in HCV<br>seropositivity.                                    | 88   |
| Table (7)    The relation between teeth extraction and HCV infection.   | 89   |
| Table (8)    Relation between blood transfusion and HCV infection.  | 90   |
| Table (9)    Relation between occupation and HCV infection.   | 91   |
| Table (10)   Relation between beard shaving habits among males and<br>HCV infection.                            | 92   |
| Table (11)   Relation between history of injection for bilharziasis and<br>HCV infection.                       | 93   |
| Table (12)   Relation between HCV infection and some risk factors.  | 94   |
| Table (13)   Liver function tests in the studied groups.  | 96   |
| Table (14)   The most important risk factors among medical personnel.   | 97   |
| Table (15)   The mean age of chronic liver diseases patients.   | 98   |
| Table (16)   Prevalence of HCV infection among patients with C.L.D.   | 99   |
| Table (17)   Prevalence and relationship of anti-HCV, serological   | 101  |

markers of HBV and bilharzial antibodies in patients  
with chronic liver diseases.

|            |   |     |
|------------|---|-----|
| Table (18) | Estimation of AFP in patients with chronic liver diseases.  | 102 |
| Table (19) | Estimation of CEA in patients with chronic liver diseases.  | 107 |
| Table (20) | Estimation of AST in patients with chronic liver diseases.  | 112 |
| Table (21) | Level of ALT among C.L.D. patients.   | 117 |
| Table (22) | Level of ALP among C.L.D. patients.   | 122 |
| Table (23) | Total bilirubin among C.L.D. patients.  | 123 |
| Table (24) | Serum Albumin among C.L.D. patients.  | 128 |
| Table (25) | Level of S. total proteins among C.L.D. patients.   | 133 |
| Table (26) | Level of $\gamma$ -glutamyl transferase among C.L.D. patients.  | 138 |
| Table (27) | Relation between HCV infection and some risk factors<br>among C.L.D patients below age 40 years.                | 139 |
| Table (28) | Relation between HCV seropositivity and education<br>among C.L.D patients below age 40 years.                   | 141 |
| Table (29) | Relation between beard shaving habits among males and<br>HCV infection among C.L.D patients above age 40 years. | 143 |
| Table (30) | Relation between HCV seropositivity and education<br>among C.L.D patients above age 40 years.                   | 144 |
| Table (31) | Relation between HCV infection and some risk factors<br>among C.L.D patients above age 40 years.                | 145 |
| Table (32) | The most important risk factors among patients<br>with C.L.D.   | 149 |
| Table (33) | The mean age of employees group.  | 150 |

|            |   |     |
|------------|---|-----|
| Table (34) | Prevalence of HCV infection among employees group.                                  | 151 |
| Table (35) | Relation between sex and HCV infection.   | 153 |
| Table (36) | Relation between teeth extraction and HCV infection.                                | 154 |
| Table (37) | Relation between blood transfusion and HCV infection.                               | 155 |
| Table (38) | Relation between beard shaving habits among males and<br>HCV infection.             | 156 |
| Table (39) | Relation between history of injection for bilharziasis and<br>HCV infection.        | 157 |
| Table (40) | Relation between education and HCV infection.                                       | 158 |
| Table (41) | Relation between HCV infection and some risk factors.                               | 159 |
| Table (42) | Liver function tests among employees group .  | 161 |
| Table (43) | The most significant risk factors among employees.                                  | 162 |
| Table (44) | Response to therapy concerning HCV RNA after 6<br>months of treatment.              | 164 |
| Table (45) | Response to therapy concerning HCV RNA after 12<br>months of treatment.             | 164 |
| Table (46) | Response to therapy concerning HCV RNA after 6<br>months of cessation of treatment. | 165 |
| Table (47) | Initial evaluation of ALT in two groups.  | 167 |
| Table (48) | Response to therapy concerning ALT after 6 months.                                  | 168 |
| Table (49) | Response to therapy concerning ALT after 12 months.                                 | 169 |
| Table (50) | Response to therapy concerning ALT after 6 months of<br>cessation of therapy.       | 170 |

# List of Figures

|  | <b>Page</b> |
|--|-------------|
| Fig. (1) Putative structure of the HCV genome.   | 5           |
| Fig. (2) Predicted genomic organization of HCV, with putative function of viral proteins.  | 6           |
| Fig. (3) Schematic presentation of strips used in RIBA test.   | 35          |
| Fig. (4) Composition of the yeast recombinant HCV antigen C <sub>100-3</sub> used to capture circulating antibodies by ELISA 1 <sup>st</sup> generation. | 35          |
| Fig. (5) Suggested treatment guidelines for alpha interferon in chronic hepatitis C.   | 51          |
| Fig. (6) Prevalence of HCV seropositive among medical personnel  | 86          |
| Fig. (7) The most important risk for HCV infection among medical personnel group.  | 95          |
| Fig. (8) Prevalence of HCV antibody among patients with chronic liver diseases.  | 100         |
| Fig. (9) Level of AFP among cirrhotic patients.  | 103         |
| Fig. (10) Level of AFP among patients with C.A.H.  | 104         |
| Fig. (11) Level of AFP among patients with C.A.H and cirrhosis.  | 105         |
| Fig. (12) level of AFP among patients with hepatosplenomegaly.   | 106         |
| Fig. (13) Level of CEA among cirrhotic patients.   | 108         |
| Fig. (14) level of CEA among patients with C.A.H.  | 109         |

|           |   |     |
|-----------|---|-----|
| Fig. (15) | Level of CEA among patients with C.A.H and cirrhosis.                   | 110 |
| Fig. (16) | Level of CEA among patients with hepatosplenomegaly.                    | 111 |
| Fig. (17) | Level of AST among cirrhotic patients.                                  | 113 |
| Fig. (18) | Level of AST among patients with C.A.H.                                 | 114 |
| Fig. (19) | Level of AST among patients with C.A.H and cirrhosis.                   | 115 |
| Fig. (20) | Level of AST among patients with hepatosplenomegaly.                    | 116 |
| Fig. (21) | Level of ALT among cirrhotic patients.                                  | 118 |
| Fig. (22) | Level of ALT among patients with C.A.H.                                 | 119 |
| Fig. (23) | Level of ALT among patients with C.A.H and cirrhosis.                   | 120 |
| Fig. (24) | Level of ALT among patients with hepatosplenomegaly.                    | 121 |
| Fig. (25) | Level of Serum T.bilirubin among cirrhotic patients.                    | 124 |
| Fig. (26) | Level of Serum T.bilirubin among patients with C.A.H.                   | 125 |
| Fig. (27) | Level of Serum T. bilirubin among patients with C.A.H<br>and cirrhosis. | 126 |
| Fig. (28) | Level of Serum T.bilirubin among patients with<br>hepatosplenomegaly.   | 127 |
| Fig. (29) | Level of Albumin among cirrhotic patients.                              | 129 |
| Fig. (30) | Serum Albumin among patients C.A.H.                                     | 130 |
| Fig. (31) | Serum Albumin among patients with C.A.H and cirrhosis.                  | 131 |
| Fig. (32) | Serum Albumin among patients with hepatosplenomegaly.                   | 132 |
| Fig. (33) | Serum T. proteins among cirrhotic patients.                             | 134 |

|           |   |     |
|-----------|---|-----|
| Fig. (34) | Serum T. proteins among patients with C.A.H.  | 135 |
| Fig. (35) | Serum T. proteins among patients with C.A.H and cirrhosis.  | 136 |
| Fig. (36) | Serum T. proteins among patients with hepatosplenomegaly.   | 137 |
| Fig. (37) | The most important risk factors among patients with chronic liver diseases below age 40 years.  | 142 |
| Fig. (38) | Relation between HCV infection and some risk factors among patients with C.L.D. above 40 years.   | 146 |
| Fig. (39) | Comparison between the most important risk factors among patients with C.L.D below and above 40 years.  | 147 |
| Fig. (40) | Prevalence of HCV seropositivity among employees.   | 152 |
| Fig. (41) | The most important risk factors for HCV infection among employees.  | 160 |
| Fig. (42) | Response to treatment concerning HCV RNA at different regimen of treatment at three time points, 6 months of treatment, end of treatment and sustained after 6 months of therapy cessation. | 166 |
| Fig. (43) | Response to treatment concerning ALT at different regimen of treatment after 6 months of treatment, 12 months (end of treatment) and sustained after 6 months of therapy cessation.         | 171 |